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Loss of glucose-stimulated insulin from
islet b cells heralds the onset of type 2
diabetes (T2D). Gooding et al.
demonstrate a glucose-induced increase
in a purine/nucleotide pathway
intermediate, adenylosuccinate (S-AMP),
and show that this metabolite is capable
of stimulating insulin exocytosis in b cells
obtained from normal and T2D humans.
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Pancreatic islet failure, involving loss of glucose-
stimulated insulin secretion (GSIS) from islet b cells,
heralds the onset of type 2 diabetes (T2D). To search
for mediators of GSIS, we performed metabolomics
profiling of the insulinoma cell line 832/13 and uncov-
ered significant glucose-induced changes in purine
pathway intermediates, including a decrease in ino-
sinemonophosphate (IMP) and an increase in adeny-
losuccinate (S-AMP), suggesting a regulatory role for
the enzyme that links the two metabolites, adenylo-
succinate synthase (ADSS). Inhibition of ADSS or a
more proximal enzyme in the S-AMP biosynthesis
pathway, adenylosuccinate lyase, lowers S-AMP
levels and impairs GSIS. Addition of S-AMP to the
interior of patch-clamped human b cells amplifies
exocytosis, an effect dependent upon expression of
sentrin/SUMO-specific protease 1 (SENP1). S-AMP
also overcomes the defect in glucose-induced
exocytosis in b cells from a human donor with T2D.
S-AMP is, thus, an insulin secretagogue capable of
reversing b cell dysfunction in T2D.
INTRODUCTION
Both type 1 and type 2 diabetes are diseases of insulin defi-
ciency, albeit with different etiologies. Type 1 diabetes (T1D)
occurs when pancreatic islet b cells are destroyed by the host
immune system. Type 2 diabetes (T2D) involves loss of key b
cell functions, such as glucose-stimulated insulin secretion
(GSIS), coupled with gradual depletion of b cell mass by non-
autoimmune mechanisms (Muoio and Newgard, 2008). A clearer
understanding of b cell function is critical for ultimate success in
the creation of surrogate cells for insulin replacement therapy
in T1D and development of better drugs for enhancing b cell
function in T2D. Here we have focused on metabolic coupling
mechanisms in the b cell and how they are altered when islets
fail in diabetes.CFor over 30 years, one particular model of glucose stimulus/
secretion coupling has gained wide acceptance. In this
construct, glucose-driven increases in the ATP:ADP ratio inhibit
ATP-sensitive K+ channels (KATP channels), resulting in plasma
membrane depolarization, activation of voltage-gated Ca2+
channels, and influx of extracellular Ca2+, which serves to acti-
vate granule exocytosis (Bryan et al., 2005; Henquin et al.,
2003; Newgard and Matschinsky, 2001). The KATP channel-
dependent mechanism appears to be particularly important in
the first, acute phase of insulin release. In the second and sus-
tained phase of insulin secretion, closure of KATP channels is
required as an initiating event, but does not fully explain the
amplification of insulin secretion after initial glucose stimulation
(Gembal et al., 1992; Sato et al., 1992; Straub and Sharp,
2002). In fact, amplifying signals contribute as much as 60% of
total GSIS (Henquin et al., 2003), but mechanisms driving this
component of the secretory response are still incompletely un-
derstood. Growing evidence implicates non-oxidative, anapler-
otic metabolism of glucose as an important regulator of GSIS.
In particular, the full GSIS response requires pyruvate carbox-
ylase activity, efficient export of citrate and/or isocitrate from
the mitochondria to the cytosol, and engagement of isocitrate
with the cytosolic, NADP-dependent isocitrate dehydrogenase
(IDH1 or ICDc) (Gooding et al., 2015; Ferdaoussi et al., 2015;
Jensen et al., 2006, 2008; Joseph et al., 2006; Lu et al., 2002;
Ronnebaum et al., 2006).
It has been recognized for some time that glucose stimulation
of b cells causes broad-scale changes in an array of nucleotides
and their biosynthetic precursors (Detimary et al., 1996). In our
study, we applied a targeted liquid chromatography-tandem
mass spectrometry (LC-MS/MS)-based method to probe this
response in more detail. We found that exposure of the robustly
glucose-responsive INS-1-derived insulinoma cell line 832/13 to
stimulatory glucose concentrations results in a striking increase
in adenylosuccinate (S-AMP) levels. Furthermore, molecular or
pharmacological manipulation of S-AMP levels results in alter-
ations in insulin secretion that are consistent with a regulatory
role for this metabolite. Using patch-clamped human b cells
and insulinoma cells, we were able to add S-AMP to the cell
interior via the patch pipette. S-AMP enhances insulin granule
exocytosis in 832/13 cells and non-diabetic human b cells,ell Reports 13, 157–167, October 6, 2015 ª2015 The Authors 157
Figure 1. Targeted Nucleotide Profiling of 37 Metabolites in 832/13
Cells
The 832/13 cells were harvested after 2 hr exposure to either 2.5 mM
(gray bars) or 12 mM (black bars) glucose and analyzed by LC-MS/MS for
nucleotide content. Data are expressed as average ± SE of five independent
experiments performed in triplicate. +p < 0.05 relative to 2.5mMglucose; @p <
0.01 relative to 2.5 mM glucose as calculated by Wilcoxon rank-sum test. Full
compound names and acquisition parameters for LC-MS/MS analyses are
shown in Table S1.and, when applied to b cells from a human donor with T2D,
S-AMP completely reverses the defect in the glucose-depen-
dent amplification of exocytosis. We also present evidence
that S-AMP-mediated facilitation of granule exocytosis requires
sentrin/SUMO-specific protease 1 (SENP1). These findings
identify S-AMP as ametabolic intermediate that couples glucose
metabolism to insulin secretion and that is able to reverse b cell
dysfunction in T2D.
RESULTS
Glucose-Induced Changes in Purine Pathway
Intermediates and Nucleotides
We applied a targeted LC-MS/MS assay method for measuring
glucose-induced changes in 37 nucleotides and purine pathway
intermediates in islet b cells. Our goal was to determine if any re-
gulatedmetabolites could be ascribed a role in GSIS. Stimulation
of the robustly glucose-responsive rat insulinoma cell line 832/13
with 12mMglucose for 2 hr caused an increase in PRPP (1.9-fold,
p = 0.038), but nodetectable changes in othermetabolites of early
de novo purine synthesis (acadesine and 5-aminoimidazole-4-
carboxamide ribonucleotide [ZMP]) relative to cells treated with
basal glucose (2.5 mM glucose) (Figure 1). Glucose stimulation
significantly changed the concentrations of intermediates later
in the pathway, including inosine monophosphate (IMP) (77%
decrease, p = 1.3 3 108), S-AMP (3.4-fold increase, p = 4.0 3
105), hypoxanthine (73% decrease, p = 0.024), and ATP (18%
decrease, p = 0.013). Other purine (AMP, ADP, XMP, GMP,
GDP, and GTP) and pyrimidine (CMP, CDP, CTP, UMP, UDP,
and UTP) nucleotides did not change significantly in response to158 Cell Reports 13, 157–167, October 6, 2015 ª2015 The Authorsstimulatory glucose. Oxidized pyridines tended to decrease in
concentration (NAD 16%; NADP 27%), whereas their reduced
forms increased significantly (NADH 2.4-fold, p = 0.009; NADPH
1.8-fold, p = 0.05) in response to stimulatory glucose. Nucleotide
conjugatesGDP-mannose (3.7-fold increase, p = 4.13 106) and
50-methylthioadenosine (MTA) (35% decrease, p = 0.046) also
changed dynamically with glucose.
MPA Inhibition of GSIS from 832/13 Cells Is Rescued by
the Provision of Guanine
Inosine monophosphate dehydrogenase (IMPDH; EC 1.1.1.205)
catalyzes the NAD-dependent conversion of IMP to XMP, and is
considered to be the rate-limiting step in the de novo biosyn-
thesis of guanine nucleotides. Two IMPDH isoforms are ex-
pressed in mammalian cells, encoded by distinct genes that
share 84% amino acid identity and with similar catalytic activity
(Carr et al., 1993; Hager et al., 1995; Natsumeda et al., 1990). The
quantitative real-time PCR analysis of IMPDHmRNA levels in rat
islets and 832/13 cells revealed that IMPDH2 is the more abun-
dant isoform in both settings, being 6.7 ± 1.2-foldmore abundant
than IMPDH1 in rat islets (n = 4 independent islet samples, each
measured in triplicate) and 9.7 ± 2.3-fold higher in 832/13 cells
(n = 7 independent samples, each measured in duplicate). To
test the role of the guanine arm of purine biosynthesis in the con-
trol of GSIS, we applied mycophenolic acid (MPA), a selective,
reversible, and noncompetitive inhibitor of both isoforms of
IMPDH (Kitchin et al., 1997), to 832/13 cells. MPA inhibited
GSIS in a dose-dependent manner (Figure 2A). Co-culture with
100 mM guanine fully reversed the strong inhibitory effect of
2 mg/ml MPA on GSIS (Figure 2B), whereas 250 mM adenine
caused only a minimal improvement.
Effects of MPA on Nucleotide Levels
To further understand the inhibitory effect of MPA on GSIS and
the discrete restorative effects of guanine versus adenine addi-
tion, we explored the effects of these agents on nucleotide pools
in 832/13 cells exposed to 12 mM glucose (Figures 2C and S1).
As expected, treatment with 2 mg/ml MPA caused increases in
upstream purine pathway intermediates, such as PPRP, acade-
sine, ZMP, and IMP (all p% 0.05). Also as expected, metabolites
in the guanine nucleotide pathway, including guanosine, GMP,
GDP, andGTP, decreased in response to the inhibition of IMPDH
with MPA (all p < 0.05). Surprisingly, MPA-treated cells also had
lower levels of adenine metabolites, including S-AMP, AMP,
ADP, and ATP (all p < 0.05), demonstrating that a block in the
guaninemetabolic pathway impacts production of intermediates
of adenine metabolism.
Consistent with their divergent effects on rescue of GSIS in
MPA-treated cells, guanine and adenine addition had discrete
effects on purine and nucleotide metabolites when added in
the presence of MPA. Under these conditions, both guanine
and adenine addition lowered the levels of the precursor metab-
olites PRPP, acadesine, and ZMP back to levels observed in
control cells or lower. In the presence of MPA plus adenine,
levels of guanosine, GMP, GDP, GTP, S-AMP, AMP, ADP, and
ATP were all lower than in control cells (no MPA, no nucleobase
addition), with p < 0.01 (Figure 2C). In contrast, all of the forego-
ing analytes were equal to or greater than control in the presence
Figure 2. Guanine, but Not Adenine, Res-
cues the Inhibitory Effects of MPA on GSIS
and Purine Metabolites
(A and B) Insulin secretion from 832/13 cells
measured (A) in the presence or absence of my-
cophenolic acid (MPA) addition or neither (ON),
during preincubation and GSIS; and (B) with or
without adenine (250 mM) or guanine (100 mM)
addition in combination with MPA. Data are ex-
pressed as average ± SE of three independent
experiments performed in triplicate. *p < 0.05
relative to no MPA; #p < 0.05 relative to +MPA.
(C) The 832/13 cells were treated with MPA
(2 mg/ml) in the presence of adenine (A) or guanine
(G), or neither (), during preincubation and
glucose stimulation (12 mM). Purine concentra-
tions were quantified by LC-MS/MS. Data are ex-
pressed as average ± SE in nmol metabolite/mg
protein of three independent experiments per-
formed in triplicate. See Figure S1 for quantifica-
tion of additional metabolites.of MPA plus guanine. In other words, guanine, but not adenine,
was able to reverse the effects of MPA to lower these metabo-
lites, in concert with guanine’s unique ability to rescue GSIS.
Pharmacologic Inhibition and siRNA-Mediated
Suppression of ADSS Impairs GSIS
One potential explanation for the surprising effect of guanine to
rescue adenine nucleotide pools and GSIS is that GTP is a
cofactor for adenylosuccinate synthase (ADSS; EC 6.3.4.4),
which catalyzes conversion of IMP and aspartic acid to
S-AMP. In mammals, two isozymes are present. ADSS1 is highly
abundant in cardiac and skeletal muscle tissues and is thought
to play a role in energy metabolism via the purine nucleotide cy-
cle. ADSS2 is present at low levels in most tissues and functions
in de novo AMP biosynthesis (Stayton et al., 1983). Interestingly,
ADSS2 is more abundant than ADSS1 in rat islets and 832/13
cells, with 26 ± 5-fold more ADSS2 than ADSS1 mRNA in rat is-
lets, and 15 ± 1-fold more in 832/13 cells. To test the role of
ADSS in GSIS, we treated 832/13 cells with small interfering
RNA (siRNA) duplexes specific for ADSS1 and ADSS2, resulting
in 71% ± 3% and 84% ± 3% decreases in mRNA expression,
respectively (Figure 3A). These manipulations had no effect onCell Reports 13, 157–16basal insulin output (Figure 3B), but
knockdown of ADSS2 caused 38% and
29% decreases in insulin secretion at
12 mM glucose compared to mock-trans-
fected (no duplex [ND]) cells or cells
treated with a control siRNA duplex
(siCont), respectively (p < 0.01 for both
controls). In cells treated with siADSS1,
insulin secretion at 12 mM glucose was
reduced relative to ND (p < 0.01) but did
not reach significance relative to siCont
(p = 0.094). Simultaneous knockdown of
ADSS1 and ADSS2 (by 63% ± 8% and
78% ± 4% compared to ND, respectively)suppressed GSIS to the same extent as knockdown of ADSS2
alone. These findings were confirmedwith a second set of siRNA
duplexes targeting ADSS1 and ADSS2 (data not shown).
When added to cells, alanosine is converted by SAICAR syn-
thase to 5-amino-4-imidazole carboxylic acid, a powerful and
selective inhibitor of ADSS (Ki 0.3 mM) (Jayaram et al.,
1979). We therefore determined if the inhibitory effects of
siADSS duplexes on GSIS were recapitulated by alanosine
exposure. Treatment of 832/13 cells with 20 mg/ml alanosine
significantly reduced insulin secretion at 12 mM glucose (p <
0.001) without affecting basal insulin secretion (p = 0.7) (Fig-
ure 3D). Alanosine also had a dose-dependent effect to inhibit
GSIS in primary rat islets, with a 15% decrease at 20 mg/ml
and a 40% decrease at 100 mg/ml at stimulatory glucose
(16.7 mM) (Figure 3C). Provision of adenine completely reversed
the inhibitory effect of 20 mg/ml alanosine on GSIS in 832/13
cells (p < 0.01).
Effects of Alanosine on Nucleotide Levels
To explore the mechanism of alanosine inhibition on GSIS, we
performed nucleotide profiling in 832/13 cells treated overnight
and during the insulin secretion assay with 20 mg/ml alanosine7, October 6, 2015 ª2015 The Authors 159
Figure 3. Pharmacologic or Molecular Inhi-
bition of ADSS Expression Impairs GSIS
(A and B) The 832/13 cells were mock-transfected
(ND), or transfected with either a control siRNA
(siCont) or siRNA duplexes targeting ADSS1 or 2,
and kept in culture for 72 hr prior to (A) quantitative
real-time PCR analyses or (B) insulin secretion
analyses. *p < 0.01 relative to ND and siCont; #p <
0.01 relative to ND.
(C and D) Insulin secretion from primary rat islets
(C) or 832/13 cells (D) incubated with various
doses of alanosine (alano) for 20 hr in the presence
(+A) or absence () of adenine. +p < 0.05 relative
to no alanosine control; @p < 0.01 relative to no
alanosine control. Data in (A)–(D) represent the
average ± SE of three to four independent exper-
iments performed in triplicate.
(E) The 832/13 cells were treated with alanosine
(20 mg/ml) in the presence (A) or absence ()
of adenine (100 mM) or during preincubation
and glucose stimulation (12 mM), as indicated.
Purine concentrations were quantified by LC-
MS/MS. Data are expressed as average ± SE
in nmol metabolite/mg protein for two inde-
pendent experiments performed in triplicate.
See Figure S2 for quantification of additional
metabolites.(Figures 3E and S2). As anticipated, inhibition of ADSS with ala-
nosine caused increases in upstreammetabolites such as PRPP,
ZMP, acadesine, and IMP (all p < 0.05). ADSS inhibition also
decreased the concentration of its enzyme product, S-AMP,
by 52% (p = 0.0022), as well as the pools of downstream
products adenosine, AMP, ADP, and ATP (all p < 0.01). Some
products of the guanine pathway tended to increase in
alanosine-treated cells (XMP 4.3-fold, p = 0.26; GMP 1.9-fold,160 Cell Reports 13, 157–167, October 6, 2015 ª2015 The Authorsp = 0.0022), indicating that ADSS inhibi-
tion may cause some diversion of IMP
through the IMPDH reaction.
The addition of 100 mM adenine to
alanosine-treated cells lowered the
concentrations of upstream metabolites
(PRPP, ZMP, and acadesine) back to
or below the levels of controls, and
raised downstream metabolite concen-
trations (S-AMP, adenosine, AMP, ADP,
and ATP) back to control levels.




In evaluating our nucleotide profiling
data, we were particularly intrigued
with the 3.4-fold increase in S-AMP
in response to stimulatory glucose,
because this increase was in the oppo-
site direction of metabolites directly up-
stream (IMP 77% decrease, aspartate59% decrease) in its metabolic pathway, and in the same direc-
tion as its degradation product fumarate (Ferdaoussi et al.,
2015; Jensen et al., 2006). These findings implicate S-AMP as
a candidate stimulus/secretion coupling factor. Also supporting
this idea, GSIS was impaired in response to molecular or phar-
macologic suppression of ADSS, the enzyme that generates
S-AMP (Figure 3). Moreover, S-AMP levels were rescued by
the provision of guanine in MPA-treated cells and adenine in
Figure 4. Time Course of Glucose-Stimu-
lated S-AMP Changes and Effect of S-AMP
to Augment the Exocytotic Response of
832/13 Cells to Membrane Depolarization
(A and B) GSIS (A) and changes in S-AMP levels (B)
in 832/13 cells incubated at basal (2.5 mM) or
stimulatory (12mM) glucose for 30 or 120min (n = 2
independent experiments, each assayed in tripli-
cate and expressed as average ± SE; *p < 0.001
compared to basal glucose).
(C and D) Cumulative exocytosis over ten de-
polarizations (C) and the total exocytotic response
(D) in 832/13 cells following acute glucose (10 mM)
exposure, or upon infusion of S-AMP (10 mM), AMP
(10 mM), or fumarate (10 mM) (n = 22, 24, 26, 19, and
20 cells, respectively). Data are expressed as
average ± SE. *p < 0.01 and #p < 0.05 compared to
basal glucose; @p < 0.05 compared to 10 mM
glucose; ns, not significant.alanosine-treated cells, in concert with the rescue of GSIS in
both cases (Figures 2 and 3).
As a first step in evaluating S-AMP as a potential coupling fac-
tor for insulin secretion, we sought better understanding of the
time course of its response to glucose, since all of the nucleotide
profiling shown in Figures 1, 2, and 3 was performed after 2 hr of
exposure to basal or stimulatory glucose. If S-AMP is relevant as
an insulin secretagogue, its levels should increase at time points
at which insulin secretion is initiated, earlier than 2 hr. We there-
fore performed measurements of GSIS and S-AMP levels at
30 min and 120 min in 832/13 cells incubated at basal
(2.5 mM) and stimulatory (12 mM) glucose. We observed robust
stimulation of GSIS (Figure 4A) in concert with strong and signif-
icant increases in S-AMP at both time points (Figure 4B). These
data show that S-AMP levels are responsive to glucose over a
time frame that is consistent with a role for this metabolite in
the regulation of GSIS.
S-AMP is not expected to be membrane permeant, so in or-
der to test its potential role as an insulin secretagogue, we per-
formed patch-clamp studies on 832/13 cells using membrane
capacitance as a measure of insulin granule exocytosis (Kanno
et al., 2004). With this system, compounds such as S-AMP can
be readily introduced to the interior of the cell via the patch
pipette. In patch-clamped 832/13 cells, we observed a 2.9-
fold amplification of exocytosis in cells pre-treated with
10 mM compared with 1 mM glucose (Figures 4C and 4D;
n = 22–24 cells, p < 0.001). Remarkably, when tested in the
presence of 1 mM glucose, 10 mM S-AMP was an even more
potent facilitator of exocytosis than 10 mM glucose, resulting
in a 4.1-fold increase in the exocytotic response relative to
1 mM glucose alone (Figures 4C and 4D; n = 26 cells, p <
0.001). S-AMP was further metabolized to yield AMP and
fumarate by adenylosuccinate lyase (ADSL). Consistent with a
specific effect of S-AMP on exocytosis, 10 mM AMP had no sig-
nificant effect on exocytosis (n = 19 cells, p = 0.9), whereasCell Reports 13, 157–1610 mM fumarate increased exocytosis
1.8-fold over basal levels (n = 19 cells,
p < 0.05), a significant but clearly lessereffect compared to glucose or S-AMP (p < 0.01; Figures 4C
and 4D).
Suppression of ADSL Expression Lowers S-AMP and
Impairs GSIS
ADSL plays two important roles in nucleotide metabolism,
serving first to catalyze a proximal step in the purine biosynthetic
pathway, the conversion of SAICAR to AICAR (ZMP), and then
also acting to degrade S-AMP to AMP and fumarate more
distally. Since knockdown of ADSL could slow biosynthesis
of S-AMP and/or inhibit its degradation, with no certain net
outcome, we decided to test the effect of siRNA-mediated sup-
pression of the enzyme directly. Accordingly, we used an siRNA
duplex to suppress ADSLmRNA levels by approximately 50% in
832/13 cells, resulting in clear impairment of GSIS (Figure 5A).
Consistent with a dominant role of ADSL in proximal steps of
the purine pathway, ADSL knockdown also caused a clear
decrease in S-AMP levels at stimulatory glucose levels (Fig-
ure 5B). Unlike inhibition of IMPDH or ADSS, ADSL knockdown
did not result in decreases in other adenine nucleotides (AMP,
ADP, and ATP; Figure 5B) or GTP (data not shown), and in fact
caused small increases in AMP, ADP, and ATP levels (Figure 5B).
These data are consistent with a regulatory role of S-AMP in
GSIS that is independent of other nucleotides.
Effects of S-AMP on Exocytosis in b Cells from
Non-diabetic Human Donors
Next, we investigated if the effect of S-AMPon exocytosis in 832/
13 cells extrapolates to primary human b cells. In dispersed and
reaggregated islet cells from normal (non-diabetic) donors, insu-
lin secretion was increased by 3.3-fold in response to 16.7 mM
glucose relative to 2.5 mM glucose (Figure 6A). Patch clamping
of b cells from the same donors following an acute (10–
15 min) increase of glucose from 1 to 10 mM revealed a 2.2-
fold increase in depolarization-induced exocytosis (n = 15–177, October 6, 2015 ª2015 The Authors 161
Figure 5. Effect of ADSL Knockdown on GSIS, S-AMP, and Adenine
Nucleotide Levels
The 832/13 cells were treated with an siRNA duplex specific for ADSL (siAdsl),
resulting in an 50% decrease in ADSL mRNA levels compared to cells
treated with a nontargeting siRNA (siCont) or untreated cells (ND).
(A) The effect of ADSL knockdown on GSIS is shown.
(B) Changes in S-AMP, AMP, ADP, and ATP in ND, siCont, and SiAdsl cells are
shown. For all, n = 2 independent experiments, each assayed in triplicate and
expressed as average ± SE. *p < 0.05 compared to siCont for the same
glucose level.cells from three donors; Figure 6B). Intracellular dialysis with
10 mM S-AMP amplified the exocytotic response to membrane
depolarization-induced Ca2+ entry by 3-fold compared to
1 mM glucose alone (Figure 6B; n = 20 cells from three donors,
p < 0.01). Taken together, our results identify S-AMP as a
glucose-regulated intermediate of nucleotide metabolism that
enhances insulin granule exocytosis stimulated by membrane
depolarization in human b cells and rodent insulinoma cells.
The Amplifying Effect of S-AMP on Exocytosis Is
Dependent on SENP1
Cellular proteins can be modified by SUMOylation, the covalent
attachment of small ubiquitin-like modifier (SUMO) peptides.
These processes are reversed by the deSUMOylation enzymes
known as sentrin/SUMO-specific proteases (SENPs) (Yeh,162 Cell Reports 13, 157–167, October 6, 2015 ª2015 The Authors2009). In b cells, insulin granule exocytosis is impaired by
SUMOylation, andnutrient stimulation activatesSENP1 to remove
thesemodificationsandactivatesecretion (Dai etal., 2011;Vergari
et al., 2012; Ferdaoussi et al., 2015). To determine whether the
amplifying effect of S-AMP on exocytosis is dependent on
SENP1 activity, we used siRNA to suppress SENP1 expression
in human b cells from non-diabetic donors, leading to a 62%
decrease in SENP1 mRNA levels relative to siCont-treated cells
(n = 6 and 6 cells, respectively, from three donors, p < 0.01). This
treatment resulted in a 58% decline in the exocytotic response
following 10 mM glucose treatment compared to siCont-treated
cells (Figure 6C; n = 17 and 16 cells, respectively, from three do-
nors, p < 0.01). Similarly, knockdown of SENP1 reduced the
S-AMP-dependent facilitation of exocytosis by 50% (Figure 6C;
n = 25 and 20 cells from three donors, p < 0.01), indicating that
the full amplifying effect of S-AMP requires SENP1 activity.
S-AMP Rescues Impaired Exocytosis in Human T2D
b Cells
Given the potent effects of S-AMP to enhance exocytosis in 832/
13 cells and b cells from non-diabetic human donors, we inves-
tigated the effects of S-AMP in b cells from a human T2D donor.
As expected, the GSIS response measured in islet cell aggre-
gates from the T2D donor was impaired relative to secretion
from human islet cell aggregates from non-diabetic donors
(1.6-fold versus 3.3-fold, compare Figures 6A and 6D). Similarly,
10 mM glucose failed to potentiate depolarization-induced
exocytosis compared to 1 mM glucose in b cells from the T2D
donor (n = 8–9 cells, p = 0.6; Figure 6E). However, dialysis of
10 mM S-AMP induced an approximate 2.5-fold amplification
of depolarization-induced exocytosis in the T2D b cells (Fig-
ure 6E; n = 8 cells, p < 0.01), similar to the effect of S-AMP or
stimulatory glucose in normal human b cells (Figure 6B). Thus,
our data demonstrate that, in addition to amplifying the exocy-
totic response in non-diabetic human b cells, S-AMP rescues
dysfunctional exocytosis in human T2D b cells.
DISCUSSION
Glucose metabolism contributes to purine and nucleotide
biosynthesis via entry of glucose into the pentose monophos-
phate shunt to form ribose-5-P, on which the ring structures of
nucleotides are synthesized from glycine, glutamine, aspartate,
and 10-formyltetrahydrofolate. Several recent studies have
used metabolomics to document changes in an array of purine
and nucleotide pathway intermediates in response to glucose
challenge in the INS-1-derived 832/13 b cell line created in our
laboratory (Huang and Joseph, 2014; Lorenz et al., 2013; Spe´gel
et al., 2011). These findings provide correlative data suggesting
that some of the metabolites could function as stimulus/secre-
tion coupling factors, but direct experiments to test individual
candidate mediators have not appeared. To delve deeper into
this possibility, we employed a targeted, quantitative LC-MS/
MSmethod for survey of purine and nucleotide pathway interme-
diates. Using this method, we found a decrease in IMP, and an
increase in S-AMP in glucose-stimulated 832/13 cells, suggest-
ing that the enzyme linking the two metabolites, ADSS, could
play a regulatory role in b cell glucose sensing. Although the
Figure 6. S-AMP Increases the Exocytotic
Response of Human b Cells to Membrane
Depolarization in an SENP1-Dependent
Manner and Rescues Impaired Exocytosis
in Human T2D b cells
(A) GSIS from islet cell aggregates from non-dia-
betic human donors is shown.
(B) The total exocytotic response of non-diabetic
human b cells following acute glucose (10 mM)
stimulation or upon infusion of 10 mM S-AMP is
shown (n = 15, 17, and 20 cells from three donors).
(C) The total exocytotic response of non-diabetic
human b cells transfected with control duplex
(siScrambled; n = 14, 17, and 25 cells from three
donors) or a duplex targeting SENP1 (siSenp1, n =
13, 16, and 20 cells from three donors), following
acute glucose (10 mM) stimulation or after
administration of 10 mM S-AMP, is shown.
(D) GSIS from islet cell aggregates from a human
donor with T2D is shown.
(E) The total exocytotic response of human b cells
from a T2D donor following acute glucose (10 mM)
stimulation, or upon infusion of 10 mM S-AMP is
shown (n = 9, 8, and 8 cells from one donor). Data
are expressed as average ± SE. *p < 0.01
compared with the basal glucose condition; #p <
0.01 compared to siScrambled/10 mM glucose;
@p < 0.05 compared to siScrambled/S-AMP.glucose-induced decrease in IMP has been reported previously
(El-Azzouny et al., 2014), this is the first finding of changes in
levels of S-AMP in b cells in response to glucose stimulation.
Consistent with the concept that ADSS and its product S-AMP
have a stimulus/secretion coupling role, pharmacologic or mo-
lecular suppression of ADSS caused impairment of GSIS with
attendant decreases in S-AMP, effects that could be overcome
by the addition of adenine. Moreover, siRNA-mediated suppres-
sion of ADSL, a more proximal enzyme in the S-AMP biosyn-
thetic pathway, impaired GSIS and lowered S-AMP levels, inde-
pendent of decreases in other adenine nucleotides or GTP.
Strikingly, infusion of S-AMP into patch-clamped 832/13 cells
or b cells from non-diabetic human subjects stimulated exocy-
tosis at least as well as glucose, and S-AMP also rescued exocy-
tosis in glucose-insensitive b cells from human T2D subjects.
Recent studies report that inhibition of the pentose phos-
phate pathway enzyme glucose-6-phosphate dehydrogenase
(G6PDH) by dehydroepiandrosterone (DHEA) (Spe´gel et al.,
2013), or suppression of the subsequent step in the pathway,
6-phosphogluconate dehydrogenase (6PGDH), by siRNA or
the chemical inhibitor 6-AN (Goehring et al., 2011), results in
impaired GSIS. The effects of 6PGDH inhibition were ascribed
to the accumulation of early pentose shunt pathway intermedi-
ates and activation of p-ERK (Goehring et al., 2011), whereas
DHEA treatment was reported to cause a decrease in reduced
glutathione (GSH) levels, presumably secondary to impaired
NADPH production, although the effect of DHEA on NADPH
was not reported (Spe´gel et al., 2013). Here we show that a spe-
cific, glucose-regulated product of the pentose shunt and the
purine pathway, S-AMP, has a direct effect to augment exocy-Ctosis in normal islets, presenting an alternative explanation for
these prior findings.
Our data suggest that manipulation of S-AMP levels may pro-
vide a means of enhancing secretion in otherwise dysfunctional
islets in T2D. Currently, there is very little information available
about the impact of T2D on the purine pathway in general, or
on S-AMP levels more specifically. Earlier reports showed the
inhibitory effect of MPA on GSIS and guanine nucleotide levels,
but did not fully recognize the impact of MPA on the adenine
branch of nucleotide metabolism and did not identify S-AMP as
a regulated metabolite (Li et al., 2000). Another report described
altered adenine nucleotide metabolism in the diabetic heart in
the BB/Wistar and streptozotocin diabetes rat models, with in-
creases in the AMP catabolic enzymes 50-nucleotidase, adeno-
sine deaminase, and AMP deaminase, and apparent compensa-
tory induction of the nucleotide cycle enzymes ADSS and ADSL
(Jenkins et al., 1988), but islet studies were not reported. More
recently, a study of the thiazolidinedione (TZD)/PPARg activators
rosiglitazone and pioglitazone in normal rats revealed increases
in cardiac IMP and AMP levels in response to drug treatment,
accompanied by transcriptional upregulation of G6PDH, the
PRPP-synthesizing enzyme Prps1, and ADSS (Liu et al., 2013),
but again S-AMP was not measured and islet studies were not
performed. Interestingly, interaction of PPARg with the ADSS
promoter was reported, and TZDs are known to be protective
against the development of b cell failure and diabetes in the
Zucker diabetic fatty (ZDF) rat (Shimabukuro et al., 1998; Sreenan
et al., 1996). Additional studieswill be required to define potential
changes in the expression of key S-AMP-generating and -de-
grading enzymes in islets in rodent models and human T2D isletsell Reports 13, 157–167, October 6, 2015 ª2015 The Authors 163
Figure 7. Schematic Summary of the Role of Purine/Nucleotide
Pathways in Coupling of Glucose Metabolism and Insulin Secretion
The purine metabolic pathway is shown with metabolites that increase (red)
or decrease (blue) in response to glucose stimulation in the 832/13 cell
line. ADA, adenosine deaminase; ADSL, adenylosuccinate lyase; ADSS, ad-
enylosuccinate synthase; AK, adenylate kinase; AMPDA,AMPdeaminase; IMP,
inosine monophosphate; IMPDH, inosine 5-monophosphate dehydrogenase;
MPA, mycophenolic acid; S-AMP, adenylosuccinate.and the possible restorative effects of TZD or adenine supple-
mentation in those preparations. Conversely, one potential
explanation for the impact of ADSS suppression on GSIS could
have been a secondary perturbation of genes known to regulate
GSIS or disallowed genes associated with b cell secretory
dysfunction (Thorrez et al., 2011). However,we foundnochanges
in the expression of GLUT2; glucokinase; Kir6.2 (component
of the KATP channel); the cytosolic, NADP-dependent isoform of
isocitrate dehydrogenase (ICDc); or lactate dehydrogenase
(representative of the disallowed genes) in response to ADSS1
or ADSS2 knockdown in four separate biological samples, each
assayed in duplicate or triplicate (data not shown).
The classical model of GSIS holds that glucose-induced
increases in the ATP:ADP ratio trigger insulin secretion via inhibi-
tion of KATP channels, causing membrane depolarization and
activation of voltage-gated Ca2+ channels. Evidence for KATP
channel-independent, complementary metabolic signaling path-
ways in control ofGSIS hasbeenmounting steadily (Jensenet al.,
2008; MacDonald et al., 2005; Prentki et al., 2013; Gooding et al.,
2015). Anaplerotic metabolism of glucose in mitochondria ap-
pears to control one such complementary pathway by affecting
b cell redox status, GSH:GSSG ratio, and activity of SENP1
(Ferdaoussi et al., 2015; Ivarsson et al., 2005; Jensen et al.,
2008; Reinbothe et al., 2009). Here we show that glucose-
induced flux through de novo purine synthesis and ADSS2 drive
increases in S-AMP levels in b cells, causing enhanced insulin
granule exocytosis. During glucose stimulation, the b cell has
multiple sources of anaplerotic substrates, including pyruvate
entering through pyruvate carboxylase and conversion of gluta-
mine/glutamate to a-ketoglutarate, thus generating sufficient
levels of tricarboxylic acid (TCA) cycle intermediates to allow
their exit from the mitochondria for engagement in cytosolic,
signal-inducing pathways, most notably the pyruvate-isocitrate
pathway (Ferdaoussi et al., 2015; Jensen et al., 2008; Ronne-
baumet al., 2006). In contrast, in skeletal muscle during exercise,
anaplerotic substrates are limited, and activation of the nucleo-164 Cell Reports 13, 157–167, October 6, 2015 ª2015 The Authorstide cycle throughADSS1andADSL is thought to be an important
source of the anaplerotic metabolite fumarate, thus sustaining
the TCA cycle and ATP production. The data presented herein
are consistent with the idea that S-AMP synthesis is an important
functional role of the nucleotide cycle in islets, allowing S-AMP to
act as a glucose-induced amplifying signal for insulin granule
exocytosis (see Figure 7 for schematic summary).
Given the important role assigned to changes in the ATP:ADP
ratio in control of GSIS in the historical literature, canwe separate
the proposed signaling role of S-AMP from changes in these
other nucleotides? Several of our observations support a spe-
cific role for S-AMP. (1) Alanosine-mediated inhibition of ADSS
causes decreases in levels of S-AMP, ADP, and ATP, while
also causing impairment of GSIS. The suppression of GSIS
can be rescued by the provision of adenine, which causes
S-AMP, ADP, and ATP levels to return to normal (Figure 3). The
[ATP]/[ADP] ratio in both the suppressed and rescued states is
similar, arguing against a key role for this variable in mediating
the observed changes in GSIS under these conditions. (2) As
shown in Figure 5, silencing of ADSL results in a specific lowering
of S-AMP in concert with impairment of GSIS, with no decreases
in ADP or ATP levels or changes in ATP:ADP ratio. (3) In studies
with patch-clamped rat insulinoma and human b cells shown in
Figures 4 and 6, ATP levels are fixed and KATP channel regulation
does not occur because membrane potential is clamped in this
experimental system. Despite this, S-AMP exhibits a strong ef-
fect to amplify insulin granule exocytosis in the patch-clamped
cells. We also note that other metabolic intermediates in addition
to ATP, ADP, and changes in the ratios of these nucleotides have
been considered asmediators of GSIS. Our study focused on the
purine/nucleotide pathway, but the reader is referred to a recent
review for discussion of other implicated metabolites and path-
ways (Gooding et al., 2015).
The fundamental question of how S-AMP interacts with the
downstream secretory machinery to affect granule exocytosis
remains to be resolved. Insulin granule exocytosis is impaired
by attachment of SUMO peptides to secretory granules, and
nutrient stimulation activates SENP1 to remove these modifica-
tions and activate secretion (Dai et al., 2011; Vergari et al., 2012).
We recently have demonstrated that GSH/glutaredoxin interact
with cysteine residues required for SENP1 catalytic function,
and that the stimulatory effects of isocitrate or GSH on amplifica-
tion of exocytosis require SENP1 (Ferdaoussi et al., 2015). Here
we show that the amplifying effect of S-AMP on exocytosis
also is dependent on SENP1 activity. Whether the S-AMP/
SENP1 signaling pathway represents an independent or conver-
gent pathway relative to the pyruvate-isocitrate-GSH-SENP1
pathway remains to be investigated.
In sum, our findings have identified a potent glucose-derived
secretagogue from the purine biosynthesis pathway. Future
work will be focused on probing this pathway as a potential
source of targets for improving b cell function in T2D.EXPERIMENTAL PROCEDURES
Reagents, Cell Lines, and Primary Islets
All reagents and solutions were obtained from Sigma-Aldrich unless otherwise
indicated. The rat insulinoma cell line 832/13 was cultured as described
previously (Hohmeier et al., 2000). Rat islets were harvested from male
Sprague-Dawley rats weighing 300 g under a protocol approved by the
Duke University Institutional Animal Care and Use Committee and cultured
as described previously (Ronnebaum et al., 2008). Human islets were isolated
from pancreata of non-diabetic organ donors (n = 6) and a donor with T2D
(n = 1) at the Alberta Diabetes Institute Islet Core, as previously described
(Kin and Shapiro, 2010). All studies with human islets were approved by the
Human Research Ethics Board (Pro00001754) at the University of Alberta.
All organ donors provided informed consent for use of pancreatic tissue in
research (Pro00013094).
GSIS
Insulin secretion from 832/13 cells and rat islets (20 islets per incubation) was
measured as described previously (Jensen et al., 2006) by radioimmunoassay
(RIA) (Siemens) or ELISA (ALPCO). For GSIS from human islets, human islet cell
aggregate cultures were prepared and used as described in the Supplemental
Experimental Procedures.
IMPDH and ADSS Inhibition Experiments
For IMPDH inhibition experiments in confluent 832/13 cells, 0.1% ethanol or
MPA was added to the culture media overnight and was included during pre-
incubation and GSIS as well, with or without adenine (250 mM), guanine
(100 mM), or 0.125 N NaOH. For ADSS inhibition, L/D-alanosine (Santa Cruz
Biotechnology) was dissolved in 50 mM HEPES (pH 8.6) at several concentra-
tions and added to confluent 832/13 cells or whole rat islets, in the presence
and absence of 100 mM adenine, overnight and during performance of the
GSIS assays. Controls were treated with equal volumes of 50 mM HEPES
(pH 8.6).
siRNA-Mediated Gene Silencing of ADSS1, ADSS2, and ADSL and
Quantitative Real-Time PCR Analyses
Methods and siRNA duplex sequences used for silencing of ADSS1, ADSS2,
and ADSL in 832/13 cells, as well as the methods used for quantitative
real-time PCR analyses, are provided in the Supplemental Experimental
Procedures.
Cell Harvest for Nucleotide Extraction
After 2 hr of GSIS, media were removed and 832/13 cells were scraped from
plates in secretion buffer into a 15-ml conical tube and centrifuged. The cell
pellet was flash frozen in a dry-ice ethanol bath. A cold solution of methanol









GTP [30 mM]; 13C10-UTP [45 mM];
13C9-CTP [15 mM];
13C10-ATP [300 mM]; and
nicotinamide-1,N6-ethenoadenine dinucleotide [εNAD, 75 mM]) was added
and the pellets were allowed to thaw on ice before resuspension by pipetting.
Chilledwater (100ml) and then hexane (300ml) were added to each tube, and the
tubes were vortexed vigorously and centrifuged. The bottom aqueous layer
was collected and centrifuged again. The supernatants were transferred to a
96-well plate for analysis by LC-MS/MS.
LC-MS/MS
Themethod is amodification of a previously published approach (Cordell et al.,
2008). Chromatographic separations were performed using an Agilent Tech-
nologies 1200 HPLC system and a Chromolith FastGradient RP-18e 50-
2mm column (EMD Millipore). Injection volume was 2 ml. Mobile phase A
was 95% water, 5% methanol, and 5 mM dimethylhexylamine adjusted to
pH 7.5 with acetic acid. Mobile phase B was 20% water, 80% methanol,
and 10 mM dimethylhexylamine. Flow rate was set to 0.3 ml/min and column
temperature was 40C. A 22-min gradient method (t = 0, %B = 0; t = 1.2, %B =
0; and t = 22, %B = 40) was run followed by a 3-min wash and 7-min equilibra-
tion. Flow was directed to an Agilent 6410 Triple Quadrupole mass spectrom-
eter and source conditions were set to 4,000 V capillary voltage, 350C gas
temperature, 12 l/min gas flow, and 30 psi nebulizer flow. All nucleotides
were detected in negative ion MRM mode based on a characteristic fragmen-
tation reaction (see Table S1). Quantitation of metabolites used nine isotope-
labeled internal standards and an external calibration using serial dilution of
nucleotide standards.CSingle-Cell Measurement of b Cell Exocytosis
For patch-clamping experiments, islets were cultured in low-glucose (5.5 mM)
DMEM with L-glutamine, 110 mg/l sodium pyruvate, 10% fetal bovine serum
(FBS), and 100 U/ml penicillin/streptomycin. For SENP1 siRNA studies in hu-
man b cells, siRNA duplexes were transfected into dissociated human islet
cells with Dharmafect Transfection Reagent 1. The siSenp1 was obtained
from Life Technologies (s26615) and a scrambled siRNA (siScrambled; Allstars
negative control siRNA, QIAGEN) was used as the control. Dissociated human
islet cells or 832/13 cells were plated on 35-mm dishes overnight or for 72 hr in
the case of SENP1 knockdown experiments. Prior to patch-clamping, cells
were pre-incubated in DMEM (human) or RPMI-1640 (832/13) media with
1 mM glucose for 1 hr and then exposed to patch-clamp bath solution with
either 1 or 10 mM glucose for 15 min. Whole-cell patch-clamp was per-
formed after this, according to previously published methods (Dai et al.,
2011; Ferdaoussi et al., 2015) and as outlined in the Supplemental Experi-
mental Procedures.
Statistical Analyses
For insulin secretion, relative expression, and exocytosis experiments, statis-
tical significance was determined by two-sample, unpaired equal variance
Student’s t test. The statistical significance of metabolite concentrations
was analyzed using the Wilcoxon rank-sum test to allow for a non-normal
distribution of values due to experimental batch effects (Bauer, 1972). TheWil-
coxon test was completed using the wilcox.test function in R (R-Core Team,
2014). In all cases p values of <0.05 were considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
two figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2015.08.072.
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